$AGX

Sweeney Karen sold $212K of AGX

Sweeney Karen sold 300 shares of ARGAN INC (AGX) at $705.00 ($0.21M total) on 2026-06-17.

Original reporting
SEC EDGAR · Sweeney Karen
Published Jun 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Neutral
high confidence
Mentioned
$AGX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXNeutralLow
01

Why it matters

The disclosure updates ownership/flow information for AGX but does not introduce new operational or financial catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it still lacks motivation, tax context, or whether other insiders are selling/buying concurrently.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17 (transaction dated 2026-06-17)

Background

The article is an SEC Form 4 insider transaction disclosure for Argan Inc.

Company-level read

Ticker impact

$AGXNeutralHigh confidence
Context

Argan Inc director Sweeney Karen sold 300 shares on 2026-06-17 at $705/share, totaling $211,500, per SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless follow-on selling appears.

Evidence & confidence

The filing is an insider sale without a 10b5-1 plan and provides exact size/price, but it does not disclose new company fundamentals or guidance.

Market effects

No sector-level read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Director sales can be pre-planned for liquidity or diversification; without additional context, the sale may not reflect bearish expectations.

Key entities

  • Argan Inc

    Subject of the SEC Form 4 insider sale by a director.

  • Sweeney Karen

    Director who sold 300 shares at $705/share on 2026-06-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXHigh

Why Argan Stock Swooned by Almost 8% Today

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

$AGXMedAI 8/10

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.